Pharma Mar SA - Company Profile
Powered by
All the data and insights you need on Pharma Mar SA in one report.
- Save hours of research time and resources with
our up-to-date Pharma Mar SA Strategy Report
- Understand Pharma Mar SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Pharma Mar SA (Pharma Mar) discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed products include Yondelis (trabectedin) an antitumor agent indicated for the treatment of soft tissue sarcoma and relapsed ovarian cancer in combination with doxorubicin HCl liposome injection; Aplidin (plitidepsin), an anticancer agent for the treatment of multiple myeloma; and Zepzelca (lurbinectedin) for small cell lung cancer. Pharma Mar offers in vitro diagnostic products used for detection of virus and bacteria in respiratory infections and human papilloma virus genotypes, among others. It also offers kits used for diagnosis of influenza A and B and respiratory syncytial virus. Its development pipeline includes PM14 for solid tumors, among others. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, and the US, among others. Pharma Mar is headquartered in Madrid, Spain.
Pharma Mar SA premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Yondelis (Trabectedin) – Soft Tissue Sarcoma and Ovarian Cancer | :- |
Zepzelca (Lurbinectedin) - Small Cell Lung Cancer and Solid Tumors | Yondelis |
Aplidin - Multiple Myeloma | Aplidin |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Regulatory Approval | In March, the company's Zepzelca (lurbinectedin) has received approval from Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of the metastatic Small Cell Lung Cancer (SCLC). |
2023 | Regulatory Approval | In January, the company's licensing partner, Megapharm Ltd. received the conditional marketing approval for Zepzelca (lurbinectedin) by the Ministry of Health of Israel. |
2022 | Contracts/Agreements | In October, the company entered into an agreement with Klaria Pharma Holding AB to develop an Alginate Film formulation of a PharmaMar compound. |
Competitor Comparison
Key Parameters | Pharma Mar SA | CTI BioPharma Corp | Ability Pharmaceuticals SL | Ariad Pharmaceuticals (Spain) SL | GP Pharm SA |
---|---|---|---|---|---|
Headquarters | Spain | United States of America | Spain | Spain | Spain |
City | Colmenar Viejo | Seattle | Barcelona | Alcobendas | Barcelona |
State/Province | Madrid | Washington | Barcelona | Madrid | Barcelona |
No. of Employees | 509 | 128 | - | - | - |
Entity Type | Public | Private | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Jose Maria Fernandez Sousa-Faro, Ph.D. | Chief Executive Officer; President; Chairman | Executive Board | - | - |
Maria Luisa de Francia Caballero | Chief Financial Officer | Senior Management | - | - |
Pedro Fernandez Puentes | Vice Chairman | Executive Board | - | - |
Sandra Llamera Sanchez | Head - Global Compliance | Senior Management | - | - |
Carmen Eibe | Director - Project Coordination | Senior Management | 2003 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward